Last reviewed · How we verify
YZJ-1139
YZJ-1139 is a small molecule drug that targets the SGLT2 receptor.
YZJ-1139 is a small molecule drug that targets the SGLT2 receptor. Used for Type 2 diabetes, Heart failure.
At a glance
| Generic name | YZJ-1139 |
|---|---|
| Sponsor | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
YZJ-1139 works by inhibiting the sodium-glucose cotransporter 2 (SGLT2) in the kidneys, reducing glucose reabsorption and lowering blood glucose levels. This mechanism is particularly effective in treating type 2 diabetes. By reducing glucose reabsorption, YZJ-1139 also has a secondary effect of reducing blood pressure and fluid overload.
Approved indications
- Type 2 diabetes
- Heart failure
Common side effects
- Nausea
- Diarrhea
- Vomiting
- Hypotension
- Increased urination
Key clinical trials
- Safety and Efficacy Study of YZJ-1139 Tablets in Insomnia Disorder (PHASE3)
- A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of YZJ-1139 in Healthy Participants (PHASE1)
- PK/PD Study of YZJ-1139 (PHASE1)
- Safety and Efficacy Study of YZJ-1139 in Primary Chronic Insomnia Disorder (PHASE2)
- A Clinical Study to Evaluate the Drug Interaction Between YZJ-1139 Tablets and Escitalopram Oxalate Tablets (PHASE1)
- Pharmacokinetics and Safety Study of YZJ-1139 in Subjects With Severe Renal Impairment and Normal Renal Impairment (PHASE1)
- Pharmacokinetics and Safety Study of YZJ-1139 in Subjects With Mild, Moderate and Normal Hepatic Impairment (PHASE1)
- A Drug-drug Interaction Study of YZJ-1139 Tablets and Ticagrelor Tablets in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- YZJ-1139 CI brief — competitive landscape report
- YZJ-1139 updates RSS · CI watch RSS
- Shanghai Haiyan Pharmaceutical Technology Co., Ltd. portfolio CI